শুধুমাত্র তথ্যমূলক — চিকিৎসা পরামর্শ নয়। সর্বদা লাইসেন্সপ্রাপ্ত স্বাস্থ্যসেবা প্রদানকারীর পরামর্শ নিন।

MedBD
EN
Community data Updated 2 মাস আগে
🌐 View in English

ইঙ্গিত

Inflammatory Bowel Disease Rheumatoid Arthritis Psoriasis

Advixa injection is a tumour necrosis factor (TNF) blocker indicated for the treatment of the following conditions. Rheumatoid Arthritis (RA): To reduce signs and symptoms, induce a major clinical response, inhibit the progression of structural damage, and improve physical function in adult patients with moderately to severely active RA. Juvenile Idiopathic Arthritis (JIA): To reduce signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. Psoriatic Arthritis (PsA): To reduce signs and symptoms, inhibit the progression of structural damage, and improve physical function in adult patients with active PsA. Ankylosing Spondylitis (AS): To reduce signs and symptoms in adult patients with active AS. Adult Crohn's Disease (CD): To reduce signs and symptoms and to induce and maintain clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy. It is also used to reduce signs and symptoms and induce clinical remission in these patients if they have lost response to, or are intolerant of, infliximab. Pediatric Crohn's Disease: To reduce signs and symptoms and to induce and maintain clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate. Ulcerative Colitis (UC): To induce and sustain clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine, or 6-mercaptopurine (6-MP). The effectiveness of Advixa has not been established in patients who have lost response to, or were intolerant of, TNF blockers. Plaque Psoriasis (Ps): For the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Hidradenitis Suppurative (HS): For the treatment of moderate to severe hidradenitis suppurativa.

⚠️ কোনো ওষুধ গ্রহণের আগে সর্বদা নিবন্ধিত চিকিৎসকের পরামর্শ নিন।

ফার্মাকোলজি

Adalimumab is a laboratory-made (recombinant) human antibody, specifically an IgG1 monoclonal antibody, that targets tumor necrosis factor (TNF), a substance the body produces naturally. It works by attaching itself directly to TNF-alpha, preventing it from binding to its receptors (known as p55 and p75) on the surface of cells. In laboratory studies, it has also been shown to destroy cells that display TNF on their surface, when complement (another immune component) is present.

TNF plays a normal role in the body's inflammatory and immune responses, but when present in excess, it can drive disease. In people with Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, TNF levels are elevated in the fluid within the joints, contributing significantly to both the inflammation and the joint damage characteristic of these conditions. TNF levels are similarly raised in psoriasis plaques on the skin, and in Plaque Psoriasis, treatment with Adalimumab may help thin the skin's outer layer and reduce the presence of inflammatory cells within it.

Pregnancy & Breastfeeding

Pregnancy Category B. No adequate, well-controlled studies of Adalimumab have been carried out in pregnant women. Because Adalimumab is an IgG1 monoclonal antibody, it crosses the placenta in significant amounts once the third trimester begins. Published data suggest that only small amounts of Adalimumab pass into human breast milk, and these are unlikely to be absorbed by a breastfeeding infant. That said, no information exists on how Adalimumab is absorbed from breast milk in newborn or premature infants, so it should be given to a nursing mother only with caution.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

ডোজ নির্দেশিকা

⚠️ শুধুমাত্র সরকারি উৎস থেকে নির্দেশিকা পরিসীমা। ব্যক্তিগতকৃত ডোজের জন্য আপনার ডাক্তারের পরামর্শ নিন।

Adults: Dosage for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis is 40 mg every other week. Some patients with rheumatoid arthritis who are not receiving methotrexate may benefit from increasing the frequency to 40 mg every week. For juvenile idiopathic arthritis, children weighing 10 kg to less than 15 kg receive 10 mg every other week, those weighing 15 kg to less than 30 kg receive 20 mg every other week, and those weighing 30 kg or more receive 40 mg every other week. For adult Crohn's disease and ulcerative colitis, the initial dose on Day 1 is 160 mg, given as four 40 mg injections in one day or as two 40 mg injections per day on two consecutive days. The second dose, given two weeks later on Day 15, is 80 mg. Two weeks after that, on Day 29, the maintenance dose of 40 mg every other week begins. In ulcerative colitis only, adalimumab should be continued solely in patients who have shown evidence of clinical remission by eight weeks (Day 57) of therapy. For paediatric Crohn's disease, children weighing 17 kg to less than 40 kg receive an initial dose of 80 mg on Day 1 (two 40 mg injections in one day), a second dose of 40 mg two weeks later on Day 15, and then a maintenance dose of 20 mg every other week from Day 29. Children weighing 40 kg or more receive an initial dose of 160 mg on Day 1 (four 40 mg injections in one day or two 40 mg injections per day on two consecutive days), a second dose of 80 mg on Day 15 (two 40 mg injections in one day), and then a maintenance dose of 40 mg every other week from Day 29. For plaque psoriasis, the initial dose is 80 mg, followed by 40 mg every other week starting one week after the initial dose. For hidradenitis suppurativa, the initial dose on Day 1 is 160 mg, given as four 40 mg injections on Day 1 or as two 40 mg injections per day on Days 1 and 2. The second dose, given two weeks later on Day 15, is 80 mg (two 40 mg injections in one day). The third dose on Day 29 and all subsequent doses are 40 mg every week.